Charles Schwab Investment Management Inc. Buys 3,473 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Charles Schwab Investment Management Inc. grew its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 137,477 shares of the company’s stock after purchasing an additional 3,473 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.25% of Voyager Therapeutics worth $804,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Victory Capital Management Inc. increased its position in shares of Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after buying an additional 1,630 shares during the period. SummerHaven Investment Management LLC grew its holdings in Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after acquiring an additional 1,921 shares during the period. Hunter Perkins Capital Management LLC raised its position in shares of Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after acquiring an additional 2,025 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Voyager Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares during the period. Finally, Federated Hermes Inc. boosted its position in shares of Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after purchasing an additional 2,638 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on VYGR. Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. Wedbush assumed coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They set an “outperform” rating and a $11.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Voyager Therapeutics presently has an average rating of “Buy” and a consensus target price of $17.00.

Insiders Place Their Bets

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at $500,525.82. The trade was a 6.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.53% of the company’s stock.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $5.79 on Thursday. The stock has a market cap of $316.28 million, a price-to-earnings ratio of 8.16 and a beta of 0.90. Voyager Therapeutics, Inc. has a fifty-two week low of $5.19 and a fifty-two week high of $11.72. The firm’s 50-day simple moving average is $6.56 and its 200 day simple moving average is $7.13.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter last year, the company earned ($0.59) earnings per share. On average, sell-side analysts predict that Voyager Therapeutics, Inc. will post -0.89 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.